Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation.

abstract：:Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report fi...

journal_title：Bone marrow transplantation

authors： Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NH

更新日期：1998-10-01 00:00:00

abstract：:Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

journal_title：Bone marrow transplantation

authors： Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

更新日期：2020-10-01 00:00:00

abstract：:In the original version of this article, the mention of 'ifosfamide 1500 mg/m2 days 1-3' should, in fact, read 'ifosfamide 1500 mg/m2 bd days 1-3'. This has now been updated in the original version of the article. ...

journal_title：Bone marrow transplantation

authors： Phillips EH,Lannon MM,Lopes A,Chadwick H,Jones G,Sieniawski M,Davies A,Wood K,Clifton-Hadley L,Smith P,Lawrie A,Chadwick N,Lennard AL

更新日期：2020-04-01 00:00:00

abstract：:A cohort of 138 children with 144 hematopoietic stem cell transplantation (HSCT) performed in 1997-2006 were analyzed to evaluate risk factors and mortality predictors of hepatic veno-occlusive disease (VOD). Nineteen patients (13.2%) developed VOD (nine boys, median age 3.5 years) at 1-21 days after HSCT (median 13 d...

journal_title：Bone marrow transplantation

authors： Cheuk DK,Wang P,Lee TL,Chiang AK,Ha SY,Lau YL,Chan GC

更新日期：2007-11-01 00:00:00

abstract：:Hematopoietic stem cells are extremely sensitive to damage by ionizing radiation. At high doses of radiation, toxicity to the bone marrow may be operationally irreversible. Insufficient functional hematopoietic stem cells remain or irradiated individuals cannot survive sufficiently long enough for functional stem cell...

journal_title：Bone marrow transplantation

authors： Gale RP

更新日期：1987-06-01 00:00:00

abstract：:Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytara...

journal_title：Bone marrow transplantation

authors： Lancet JE,Rapoport AP,Brasacchio R,Eberly S,Raubertas RF,Linder T,Muhs A,Duerst RE,Abboud CN,Packman CH,DiPersio JF,Constine LS,Rowe JM,Liesveld JL

更新日期：1998-08-01 00:00:00

abstract：:High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 N...

journal_title：Bone marrow transplantation

authors： Proust-Houdemont S,Pasqualini C,Blanchard P,Dufour C,Benhamou E,Goma G,Semeraro M,Raquin MA,Hartmann O,Valteau-Couanet D

更新日期：2016-08-01 00:00:00

abstract：:We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, ...

journal_title：Bone marrow transplantation

authors： Sugita J,Kagaya Y,Miyamoto T,Shibasaki Y,Nagafuji K,Ota S,Furukawa T,Nara M,Akashi K,Taniguchi S,Harada M,Matsuo K,Teshima T,Japan Study Group for Cell Therapy and Transplantation (JSCT).

更新日期：2019-03-01 00:00:00

abstract：:Graft rejection has been a problem after bone marrow transplantation for patients with severe aplastic anemia (SAA). Ten children with SAA were conditioned for bone marrow transplantation from HLA-identical siblings, using cyclophosphamide (CY, 50 mg/kg) plus antithymocyte globulin (ATG, 15 mg/kg) for 4 successive day...

journal_title：Bone marrow transplantation

authors： Azuma E,Kojima S,Kato K,Matsuyama T,Yamada Y,Kondo N,Sawada H,Hanada M,Shibata T,Tabata N,Watanabe M,Shimono Y,Deguchi T,Umemoto M,Higashikawa M,Kawasaki H,Komada Y,Sakurai M

更新日期：1997-06-01 00:00:00

abstract：:Cytomegalovirus (CMV) antigenemia and quantitative real-time polymerase chain reaction (PCR) were compared for monitoring of CMV reactivation after allogeneic stem cell transplantation. The number of CMV antigen-positive cells by the antigenemia assay and the level of CMV DNA by real-time PCR correlated well. The sens...

journal_title：Bone marrow transplantation

authors： Yakushiji K,Gondo H,Kamezaki K,Shigematsu K,Hayashi S,Kuroiwa M,Taniguchi S,Ohno Y,Takase K,Numata A,Aoki K,Kato K,Nagafuji K,Shimoda K,Okamura T,Kinukawa N,Kasuga N,Sata M,Harada M

更新日期：2002-04-01 00:00:00

abstract：:Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that is used for psoriasis control. We recently showed its effect in acute steroid-resistant/dependent GVHD. In this study, we describe the effect of alefacept treatment on chronic extensive GVHD (cGVHD). Twelve patients were included in this study; of...

journal_title：Bone marrow transplantation

authors： Shapira MY,Abdul-Hai A,Resnick IB,Bitan M,Tsirigotis P,Aker M,Gesundheit B,Slavin S,Or R

更新日期：2009-02-01 00:00:00

abstract：:Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the ou...

journal_title：Bone marrow transplantation

authors： Cahu X,Chevallier P,Clavert A,Suarez F,Michallet M,Vincent L,Vigouroux S,Blaise D,Mariette C,Bilger K,Robin M,Yakoub-Agha I,Peffault de Latour R,Mohty M

更新日期：2014-06-01 00:00:00

abstract：:Acute GVHD remains a major problem in allogeneic BMT, in particular when donors other than HLA-identical siblings are used. To determine the efficacy of an immunomagnetic method for depletion of CD4+ and CD8+ lymphocytes from the marrow graft, a series of 15 patients was studied. Thirteen patients had matched unrelate...

journal_title：Bone marrow transplantation

authors： Jansen J,Hanks S,Akard LP,Thompson JM,Burns S,Chang Q,English D,Garrett P

更新日期：1996-03-01 00:00:00

abstract：:Autologous hematopoietic stem cell transplantation (ASCT) is curative for a proportion of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). However, there is a small group of patients with high-risk of relapse after ASCT that might benefit from other approaches. We conducted a retrospective analysis on 12...

journal_title：Bone marrow transplantation

authors： Bento L,Boumendil A,Finel H,Khvedelidze I,Blaise D,Fegueux N,Castagna L,Forcade E,Chevallier P,Mordini N,Brice P,Deconinck E,Gramatzki M,Corradini P,Hunault M,Musso M,Tsoulkani A,Caballero D,Nati S,Montoto S,Sured

更新日期：2020-10-12 00:00:00

abstract：:The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

journal_title：Bone marrow transplantation

authors： Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

更新日期：1999-12-01 00:00:00

abstract：:Children with high risk or relapsed acute lymphoblastic leukaemia (ALL) can benefit from allogeneic haematopoietic stem cell transplantation (SCT). To reduce transplantation-associated complications, the BFM study group, the IBFM study group and the PD-WP-EBMT initiated a prospective cooperative multicentre trail for ...

journal_title：Bone marrow transplantation

authors： Peters C,Schrauder A,Schrappe M,von Stackelberg A,Stary J,Yaniv I,Gadner H,Klingebiel T,BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT.

更新日期：2005-03-01 00:00:00

abstract：:Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...

journal_title：Bone marrow transplantation

authors： Abraham R,Szer J,Bardy P,Grigg A

更新日期：1997-11-01 00:00:00

abstract：:Our growing physiological understanding of hematopoietic progenitor cells has led to the clinical use of circulating progenitor cells, including stem cells, for either reconstitution of hematopoietic function, up to the transduction of functional genes into a self-renewing cell system. In the following, an attempt has...

journal_title：Bone marrow transplantation

authors： Körbling M,Fliedner TM

更新日期：1996-05-01 00:00:00

abstract：:The International Bone Marrow Transplant Registry (IBMTR), established in 1972, collects data on recipients of allogeneic bone marrow transplants from over 320 institutions, worldwide. Its database includes information for about 40% of all allogeneic transplants performed between 1964 and 1995. ...

journal_title：Bone marrow transplantation

authors： Horowitz MM,Rowlings PA,Passweg JR

更新日期：1996-05-01 00:00:00

abstract：:We retrospectively analyzed the outcome of 67 patients with breast (n=24), ovarian (n=11) or testicular cancer (n=32) treated for relapse after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) transplantation. Treatment, survival and toxicity were analyzed. Patients with breast, ovarian or testicular...

journal_title：Bone marrow transplantation

authors： Bojko P,Akca A,Seeber S

更新日期：2003-06-01 00:00:00

abstract：:We investigated the use of 'prophylactic' donor lymphocyte infusions (DLI) containing 1 x 107 CD3+ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation (BMT), following conditioning with fludarabine 30 mg/m(2)/4 days and melphalan 70 mg/m(2)/2 days. GVHD prophylaxis consisted of cyclospo...

journal_title：Bone marrow transplantation

authors： de Lima M,Bonamino M,Vasconcelos Z,Colares M,Diamond H,Zalcberg I,Tavares R,Lerner D,Byington R,Bouzas L,da Matta J,Andrade C,Carvalho L,Pires V,Barone B,Maciel C,Tabak D

更新日期：2001-01-01 00:00:00

abstract：:Chronic graft-versus-host disease (cGVHD) is a multiorgan disorder with skin manifestations resembling scleroderma. Since photopheresis, a treatment that induces an anticlonotypic immune response, has proven to be effective in both cutaneous T cell lymphomas with circulating clonal T cells and in cGVHD, we have search...

journal_title：Bone marrow transplantation

authors： French LE,Alcindor T,Shapiro M,McGinnis KS,Margolis DJ,Porter D,Leonard DG,Rook AH,Foss F

更新日期：2002-10-01 00:00:00

abstract：:Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

journal_title：Bone marrow transplantation

authors： Landgren O,Devlin S,Boulad M,Mailankody S

更新日期：2016-12-01 00:00:00

abstract：:Twenty-five patients with hematologic malignancies (n = 21) or aplastic anemia (n = 4) undergoing an allogeneic BMT from an HLA-identical sibling developed cytomegalovirus (CMV) antigenemia at a mean interval from BMT of 41 days (range 16-141 days). All patients were treated at the time of antigenemia in the absence o...

journal_title：Bone marrow transplantation

authors： Bacigalupo A,van Lint MT,Tedone E,Moro F,Sanna MA,Longren M,Trespi G,Frassoni F,Occhini D,Gualandi F

更新日期：1994-06-01 00:00:00

abstract：:Receipt of hematopoietic cell transplantation (HCT) can improve overall survival in older patients with intermediate or high-risk acute myeloid leukemia (AML); however, utilization of HCT is poor. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients....

journal_title：Bone marrow transplantation

authors： Bhatt VR,Chen B,Gyawali B,Lee SJ

更新日期：2018-10-01 00:00:00

abstract：:The role of allogeneic hematopoietic SCT (allo-HCT) in multiple myeloma (MM) remains controversial. A total of 58 patients received an allo-HCT (25 of them with myeloablative conditioning-allo-MAC-and 33 with reduced-intensity conditioning-allo-RIC) at our institution over a 28-year period. The CR rate for allo-MAC wa...

journal_title：Bone marrow transplantation

authors： Rosiñol L,Jiménez R,Rovira M,Martínez C,Fernández-Avilés F,Marín P,Suárez-Lledó M,Gutiérrez-García G,Fernández de Larrea C,Carreras E,Urbano-Ispizua A,Bladé J

更新日期：2015-05-01 00:00:00

abstract：:Numerous studies have reported the feasibility and safety of autologous SCT (ASCT) in patients with multiple myeloma (MM) and mild to moderate renal impairment, but there are limited data in dialysis-dependent patients. In this retrospective study, we reviewed the toxicities and efficacy outcomes of 33  MM patients wi...

journal_title：Bone marrow transplantation

authors： St Bernard R,Chodirker L,Masih-Khan E,Jiang H,Franke N,Kukreti V,Tiedemann R,Trudel S,Reece D,Chen CI

更新日期：2015-01-01 00:00:00

abstract：:We examined whether pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is capable of improving thrombocytopenia and promoting thrombopoietic reconstitution following lethal irradiation and bone marrow transplantation (BMT) in mice. Immediately after receiving 10 Gy whole body irradia...

journal_title：Bone marrow transplantation

authors： Kabaya K,Shibuya K,Torii Y,Nitta Y,Ida M,Akahori H,Kato T,Kusaka M,Miyazaki H

更新日期：1996-12-01 00:00:00

abstract：:We evaluated the efficacy and safety of the conditioning regimen that consisted of TBI and melphalan (L-PAM), followed by hematopoietic SCT (HSCT) in 23 children with advanced hematological malignancies. The median age at HSCT was 9 (range, 2-15) years. The underlying diseases were ALL in 16 patients (5 in CR2, 3 in C...

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Sakiyama M,Nomura Y,Teranishi H,Sasaki T,Okamura J

更新日期：2011-08-01 00:00:00

abstract：:A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

journal_title：Bone marrow transplantation

authors： Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

更新日期：2007-06-01 00:00:00